Currently out of the existing stock ratings of Thomas Smith, 61 are a BUY (74.39%), 21 are a HOLD (25.61%).

Thomas Smith

Work Performance Price Targets & Ratings Chart

Analyst Thomas Smith, carries an average stock price target met ratio of 43.63% that have a potential upside of 36.3% achieved within 118 days. Previously, Thomas Smith worked at LEERINK.

Thomas Smith’s has documented 152 price targets and ratings displayed on 28 stocks. The coverage was on Healthcare, Industrials sectors.

Most recent stock forecast was given on QTTB, Q32 Bio at 11-Dec-2024.

Wall Street Analyst Thomas Smith

Analyst best performing recommendations are on AXLA (AXCELLA HEALTH).
The best stock recommendation documented was for AXLA (AXCELLA HEALTH) at 12/15/2022. The price target of $6 was fulfilled within 1 day with a profit of $4.98 (45.36%) receiving and performance score of 453.55.

Average potential price target upside

of $64.26 (17.8%) on ARGX (ARGENX NV ADR).
of $13.02 (43.16%) on MORF (MORPHIC).
of $10.52 (35.25%) on RXDX (PROMETHEUS BIOSCIENCES).

ALLK Allakos IMVT Immunovant KROS Keros Therapeutics AXLA Axcella Health CLDX Celldex Therapeutics EQ Equillium CNTB Connect Biopharma Holdings Ltd DICE Dice Molecules Holdings LLC ELDN Eledon Pharmaceuticals ETNB 89bio GLTO Galecto LABP Landos Biopharma PRTC PureTech Health PLC RXDX Prometheus Biosciences ARGX argenx NV ADR ICPT Intercept Pharmaceuticals IMUX Immunic PRVB Provention Bio CBAY Cymabay Therapeu ETN Eaton PLC MORF Morphic PLRX Pliant Therapeutics VECT VectivBio Holding AG VRDN Viridian Therapeutics RAPT RAPT Therapeutics ALPN Alpine Immune Sciences IRON Disc Medicine QTTB Q32 Bio

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Jonathan Wolleben (JMP)